Catherine Lai, MD, MPH, discusses a study presented at the ASH Annual Meeting on the use of a new class of menin inhibitors for mutated acute myeloid leukemia. Lai, from the University of Pennsylvania, suggests that combination therapy with these inhibitors could be a key factor in leukemia treatment going forward. She also mentions the importance of sequencing these drugs and using them in combination in newly diagnosed cases. Lai discloses her involvement with various pharmaceutical companies and research funding in the field.
Source link
Menin inhibitors could significantly change leukemia treatment
